S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
Log in

La Jolla Pharmaceutical Stock Price, Forecast & Analysis (NASDAQ:LJPC)

$6.02
-0.03 (-0.50 %)
(As of 11/15/2019 04:00 PM ET)
Today's Range
$5.95
Now: $6.02
$6.40
50-Day Range
$6.03
MA: $8.03
$9.43
52-Week Range
$5.01
Now: $6.02
$16.44
Volume25,460 shs
Average Volume276,877 shs
Market Capitalization$163.38 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LJPC
CUSIPN/A
Phone858-207-4264

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.06 million
Book Value$1.12 per share

Profitability

Net Income$-199,470,000.00
Net Margins-683.88%

Miscellaneous

Employees169
Market Cap$163.38 million
Next Earnings Date3/2/2020 (Estimated)
OptionableOptionable

Receive LJPC News and Ratings via Email

Sign-up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter.


La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) released its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.05) by $0.03. The biopharmaceutical company had revenue of $5.71 million for the quarter, compared to analysts' expectations of $6.96 million. La Jolla Pharmaceutical had a negative net margin of 683.88% and a negative return on equity of 2,032.71%. View La Jolla Pharmaceutical's Earnings History.

When is La Jolla Pharmaceutical's next earnings date?

La Jolla Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for La Jolla Pharmaceutical.

What price target have analysts set for LJPC?

6 analysts have issued 1-year price objectives for La Jolla Pharmaceutical's shares. Their forecasts range from $6.00 to $20.00. On average, they anticipate La Jolla Pharmaceutical's share price to reach $14.80 in the next twelve months. This suggests a possible upside of 145.8% from the stock's current price. View Analyst Price Targets for La Jolla Pharmaceutical.

What is the consensus analysts' recommendation for La Jolla Pharmaceutical?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for La Jolla Pharmaceutical.

What are Wall Street analysts saying about La Jolla Pharmaceutical stock?

Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (8/8/2019)
  • 2. HC Wainwright analysts commented, "We base our $26 price target on a sum-of-the-parts analysis based on: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year-end 2019 fully diluted net cash of $1.69/share to arrive at our price target. We value the current commercial business at $8.76 per share and the pipeline at $15.68 per share. The commercial business value is based on a P/E multiple assumption of 30x our 2024E EPS of $0.51, discounted at 15%." (4/24/2019)

Has La Jolla Pharmaceutical been receiving favorable news coverage?

News headlines about LJPC stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. La Jolla Pharmaceutical earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for La Jolla Pharmaceutical.

Are investors shorting La Jolla Pharmaceutical?

La Jolla Pharmaceutical saw a decrease in short interest in the month of October. As of October 15th, there was short interest totalling 3,780,000 shares, a decrease of 15.2% from the September 15th total of 4,460,000 shares. Based on an average daily trading volume, of 314,600 shares, the short-interest ratio is presently 12.0 days. Approximately 14.9% of the shares of the company are sold short. View La Jolla Pharmaceutical's Current Options Chain.

Who are some of La Jolla Pharmaceutical's key competitors?

What other stocks do shareholders of La Jolla Pharmaceutical own?

Who are La Jolla Pharmaceutical's key executives?

La Jolla Pharmaceutical's management team includes the folowing people:
  • Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 59)
  • Mr. Dennis M. Mulroy, Chief Financial Officer (Age 64)
  • Ms. Jennifer A. Carver, Chief Operating Officer (Age 65)
  • Mr. James M. Rolke, Chief Scientific Officer (Age 50)
  • Dr. Lakhmir S. Chawla, Chief Medical Officer (Age 48)

Who are La Jolla Pharmaceutical's major shareholders?

La Jolla Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional investors include SG Americas Securities LLC (1.39%) and Trellus Management Company LLC (0.10%). Company insiders that own La Jolla Pharmaceutical stock include George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Laura L Douglass, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical.

Which institutional investors are buying La Jolla Pharmaceutical stock?

LJPC stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC and Trellus Management Company LLC. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical.

How do I buy shares of La Jolla Pharmaceutical?

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is La Jolla Pharmaceutical's stock price today?

One share of LJPC stock can currently be purchased for approximately $6.02.

How big of a company is La Jolla Pharmaceutical?

La Jolla Pharmaceutical has a market capitalization of $163.38 million and generates $10.06 million in revenue each year. The biopharmaceutical company earns $-199,470,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. La Jolla Pharmaceutical employs 169 workers across the globe.View Additional Information About La Jolla Pharmaceutical.

What is La Jolla Pharmaceutical's official website?

The official website for La Jolla Pharmaceutical is http://www.lajollapharmaceutical.com/.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]


MarketBeat Community Rating for La Jolla Pharmaceutical (NASDAQ LJPC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  281 (Vote Underperform)
Total Votes:  601
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel